TEVA
$13.84
Teva Pharmaceutical Industries
$1.05
8.21%
TEVA
Earnings Whisper ®
N/A
4th Quarter December 2017
Consensus:  $0.85
Revenue:  $5.33 Bil
Thursday
Feb 1
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, November 2, 2017

What do you expect when TEVA reports earnings?
Beat
Meet
Miss

Where is TEVA's stock price going from here?
Up
Flat
Down
Stock chart of TEVA
Analysts
Summary of analysts' recommendations for TEVA
Score
Grade
Pivots
Resistance
$15.55
$14.75
$14.30

$13.50

Support
$13.05
$12.25
$11.80
Tweet
Growth
Description
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Peers
CelgeneRegeneron PharmaceuticalsBioMarin PharmaceuticalVertex PharmaceuticalsJohnson & JohnsonUltragenyx PharmaceuticalEndo International plcInterCeptEli LillyZoetis